CellPryme-M question, page-18

Thanks Gavncath, that was why I posed the question. I understand that CellPryme-M quite markedly changes the cellular composition of CAR-T products. It seems too good to be true that the FDA would allow such changes without treating the resulting therapy as an entirely new product.

Which means we're unlikely to see any meaningful royalties anytime soon, if that is indeed the case. But licensing revenues, hopefully. I wonder if the manufacturers and the customers will both pay separate licensing fees and royalties.